What do systematic reviews say?

Ruxolitinib vs placebo

Ruxolitinib may leads to lower overall survival (number of deaths at compared with placebo (low certainty).

• Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis 2015 · Cochrane Headline outcomes only
  HR 0.51 [0.27, 0.98]
  1 study · 309 participants
  Low

Ruxolitinib vs best available therapy

Ruxolitinib showed no clear difference in safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4… compared with best available therapy (low certainty).

• Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis 2015 · Cochrane Headline outcomes only
  RR 1.2 [0.44, 3.28]
  1 study · 219 participants
  Low

Ruxolitinib vs best available therapy

• Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 96 participants
  Low

Ruxolitinib vs best available therapy

Ruxolitinib may leads to higher reduction in spleen size Magnetic resonance imaging or computed… compared with best available therapy (low certainty).

• Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis 2015 · Cochrane Headline outcomes only
  RR 41.78 [2.61, 669.75]
  1 study · 219 participants
  Low

Ruxolitinib vs placebo

• Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 309 participants
  GRADE not reported

Ruxolitinib vs placebo

Ruxolitinib may leads to higher safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4… compared with placebo (low certainty).

• Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis 2015 · Cochrane Headline outcomes only
  RR 9.74 [2.32, 40.96]
  1 study · 306 participants
  Low

Ruxolitinib vs placebo

Ruxolitinib may leads to higher safety (AE, adverse drug reaction): neutropenia Grades 3 or 4… compared with placebo (low certainty).

• Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis 2015 · Cochrane Headline outcomes only
  RR 3.57 [1.02, 12.55]
  1 study · 306 participants
  Low

Ruxolitinib vs placebo

Ruxolitinib may leads to higher health‐related quality of life Patients that achieved a reduction of… compared with placebo (low certainty).

• Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis 2015 · Cochrane Headline outcomes only
  RR 8.82 [4.4, 17.69]
  1 study · 309 participants
  Low

Ruxolitinib vs placebo

Ruxolitinib may leads to higher reduction in spleen size Magnetic resonance imaging or computed… compared with placebo (low certainty).

• Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis 2015 · Cochrane Headline outcomes only
  RR 64.58 [9.08, 459.56]
  1 study · 309 participants
  Low

Ruxolitinib vs best available therapy

Ruxolitinib showed no clear difference in overall survival (number of deaths at compared with best available therapy (low certainty).

• Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis 2015 · Cochrane Headline outcomes only
  HR 0.7 [0.2, 2.47]
  1 study · 219 participants
  Low

Ruxolitinib vs best available therapy

Ruxolitinib showed no clear difference in progression Free Survival (number of patients who had progression at compared with best available therapy (low certainty).

• Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis 2015 · Cochrane Headline outcomes only
  HR 0.81 [0.47, 1.39]
  1 study · 219 participants
  Low

Ruxolitinib vs best available therapy

Ruxolitinib showed no clear difference in safety (AE, adverse drug reaction): anemia Grades 3 or 4 according… compared with best available therapy (low certainty).

• Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis 2015 · Cochrane Headline outcomes only
  RR 1.35 [0.91, 1.99]
  1 study · 219 participants
  Low

Summary of findings table ‐ Oral small molecule inhibitors (ruxolitinib) vs oral small molecule inhibitors (tofacitinib)

It is very uncertain whether summary of findings table ‐ Oral small molecule inhibitors… changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with oral small molecule inhibitors (tofacitinib) (very low certainty).

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  RR 1.08 [0.77, 1.52]
  1 study · 80 participants
  Very low

Summary of findings table ‐ Oral small molecule inhibitors (ruxolitinib) vs oral small molecule inhibitors (tofacitinib)

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 80 participants
  Very low

Summary of findings table ‐ Oral small molecule inhibitors (ruxolitinib) vs oral small molecule inhibitors (tofacitinib)

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Oral small molecule inhibitors (ruxolitinib) vs oral small molecule inhibitors (tofacitinib)

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Topical small molecule inhibitors (ruxolitinib) vs placebo

Summary of findings table ‐ Topical small molecule inhibitors… showed no clear difference in short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (low certainty).

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  RR 5 [0.25, 100.89]
  1 study · 78 participants
  Low

Summary of findings table ‐ Topical small molecule inhibitors (ruxolitinib) vs placebo

It is very uncertain whether summary of findings table ‐ Topical small molecule inhibitors… changes incidence of serious adverse events compared with placebo (very low certainty).

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  RR 0.33 [0.01, 7.94]
  1 study · 78 participants
  Very low

Summary of findings table ‐ Topical small molecule inhibitors (ruxolitinib) vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Topical small molecule inhibitors (ruxolitinib) vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found